<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265680</url>
  </required_header>
  <id_info>
    <org_study_id>00-05</org_study_id>
    <nct_id>NCT01265680</nct_id>
  </id_info>
  <brief_title>Blood Sparing Strategies: Single Shot High Dose Erythropoietin Two Days Before Heart Surgery</brief_title>
  <acronym>SHOT</acronym>
  <official_title>Single High Dose Erythropoietin Obviates Transfusions: an Independent, Blinded, Prospective Randomized Study in Heart Surgery Population.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiochirurgia E.H.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiochirurgia E.H.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients operated on at the European Hospital Heart surgery Division will be randomized
      to either single dose 80.000 UI of Human Recombinant Erythropoietin and intravenous iron or
      control.

      Primary end point is the amount of transfused blood. Secondary end point is the Hemoglobin
      level in the patient on postoperative day four.

      Ancillary analysis regarding safety at 45 days and cost effectiveness are planned as well
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Growing evidence points out blood transfusion as a major determinant in medium and long term
      prognosis as regarding heart surgery population. Moreover blood has become a scarce resource,
      thus often delaying intervention due to lack of availability.

      Previous studies at our Hospital have shown that high dose Human Recombinant Erythropoietin
      (HRE)effectively spares transfusions even when administered two days before surgery. The
      previous protocol was fragmented into 5 administration which proved to be unpractical even if
      effective.

      After multidisciplinal discussion with nephrologists and transfusionists a new protocol was
      established: 80.000 UI in a single dose at time of arrival at the hospital. There are no
      exclusion criteria planned.

      Our primary end point is the amount of transfused blood. Our secondary end point is the
      Hemoglobin level in the patient on postoperative day four.

      Ancillary analysis regarding safety at 45 days and cost effectiveness are planned as well.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Use of allogenic blood transfusions</measure>
    <time_frame>In hospital stay (usually 5 to 8 days after operation)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin level on postoperative day four.</measure>
    <time_frame>Day 4 after operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Blood Transfusion</condition>
  <arm_group>
    <arm_group_label>Erythropoietin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No added administration other than our standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital.</description>
    <arm_group_label>Erythropoietin</arm_group_label>
    <other_name>Eprex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All comers

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>European Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardiochirurgia E.H.</investigator_affiliation>
    <investigator_full_name>Luca Weltert</investigator_full_name>
    <investigator_title>Project Leader Luca Weltert</investigator_title>
  </responsible_party>
  <keyword>Blood Transfusion</keyword>
  <keyword>Heart surgery</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>HRE</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

